Isotopia, CPDC ink manufacturing deal for lutetium-177

2019 12 19 00 53 5252 Hands Shaking Deal 400

Isotopia Molecular Imaging of Israel has signed a production agreement for no-carrier-added lutetium-177 (n.c.a. Lu-177) with radiopharmaceutical manufacturer Centre for Probe Development and Commercialization (CPDC) of Canada.

CPDC will produce n.c.a. Lu-177, which is used in targeted radionuclide therapy, in collaboration with Isotopia for distribution in North America, according to the companies.

Page 1 of 592
Next Page